Media.Player

Cancer Therapeutic with Increased Efficacy and Reduced Side Effects

标题

PDK Inhibitor Compounds and Methods of Use Thereof

详细技术说明

None

*Abstract

Uses Small Drug-Like Molecules to Prevent Cancer Cell Proliferation

This breakthrough approach to treating cancer is efficacious and has limited side effects. Cancer is a leading cause of death in the United States, accounting for one in four deaths annually, according to the American Cancer Society. An estimated 595,600 Americans will die of cancer-related causes in 2016, and predictions for the future continue to rise. Existing treatments often suffer from a lack of efficacy or lead to debilitating side effects for the patient. Researchers at the University of Florida have developed a distinct therapy to specifically target cancerous cell proliferation and halt the growth of tumors and the spread of cancer. This breakthrough treatment also has minimal side effects, making it a desirable treatment for both the patient and health practitioner.

Application

A therapeutic cancer treatment that inhibits the proliferation of cancer

Advantages

• Capable of preventing and treating cancer and other cell proliferation diseases, offering a therapy that is effective at a lower concentrations
• Decreases cancerous cell proliferation, inhibiting the spread of cancer to other sites and improving the probability of life expectancy
• Minimal side effects, improving patient quality of life and providing a significant market advantage

Technology

This technology is a specially designed therapeutic that treats and prevents cell proliferation diseases such as cancer. Small drug-like molecules are used to bind the dichloroacetate (DCA) binding pocket of pyruvate dehydrogenase kinase isoform 2 (PDK2) and inhibit cancer cell proliferation. A patient suffering from or susceptible to a PDK2 mediated disorder or disease is administered a therapeutically effective amount of a compound that activates PDK2 activity, thereby receiving treatment.

*IP Issue Date

Jul 23, 2013

*IP Publication Date

Jan 5, 2012

*Principal Investigation

Name: David Ostrov

Department:

Name: Arun Srivastava

Department:

Name: Peter Stacpoole

Department:

附加资料

Inventor: Charlier, Jr., Henry A. | Gerasimchuk, Nikolay
Priority Number: US7727967B2
IPC Current: A61K003170 | A01N003324 | A01N004304 | A61K003115
US Class: 514034 | 514640
Assignee Applicant: Boise State University,Boise
Title: Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
Usefulness: Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
Summary: For improving efficacy of anthracycline cancer treatment (claimed).
Novelty: Pharmaceutical composition for improving efficacy of anthracycline cancer treatment comprises anthracycline compounds and enzyme inhibitors comprising halogenated aryl group

主要类别

诊断/治疗

细分类别

癌症/肿瘤

申请日期

Jul 1, 2011

申请号码

8,492,344

其他

国家/地区

美国